NeurAxis (NASDAQ:NRXS) and Heyu Biological Technology (OTCMKTS:HYBT) Head to Head Analysis

NeurAxis (NASDAQ:NRXS) and Heyu Biological Technology (OTCMKTS:HYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for NeurAxis and Heyu Biological Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
Heyu Biological Technology	0	0	0	0	N/A

Valuation and Earnings

This table compares NeurAxis and Heyu Biological Technology’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$2.27 million	9.33	-$14.63 million	($3.73)	-0.85
Heyu Biological Technology	$80,000.00	322.65	-$270,000.00	N/A	N/A

Heyu Biological Technology has lower revenue, but higher earnings than NeurAxis.

Institutional and Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. 15.2% of NeurAxis shares are held by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares NeurAxis and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-633.10%	N/A	-926.02%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Summary

Heyu Biological Technology beats NeurAxis on 5 of the 9 factors compared between the two stocks.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.